Regional Western Australia Hosts First Commercial Chemo Nausea Trial

Regional Western Australia Hosts First Commercial Chemo Nausea Trial
Why this is good news

    Chemotherapy often causes severe nausea and vomiting, a side effect this new trial aims to prevent.

  • First regional commercial trial.Before, cutting edge drug trials were only available in major cities, forcing rural patients to travel far. Now, regional Western Australians can access this study locally, reducing their burden.
  • Targeted nausea relief.The YAAD trial tests a new medicine specifically for chemotherapy induced nausea and vomiting. If effective, it could give patients a better option than current treatments, which often fail to fully control symptoms.
  • Phase 2 scientific rigor.This double-blind, placebo controlled design means results will be reliable and unbiased. Patients and doctors will know for sure if the new drug works, not just hope it does.
  • Expanding rural healthcare.The WA Country Health Service Clinical Trial Centre is now hosting advanced research, proving regional hospitals can lead medical breakthroughs. This opens the door for more future trials in underserved areas.

Patients undergoing chemotherapy in regional Western Australia are now part of a groundbreaking study that could change how cancer treatment side effects are managed. For the first time, a commercially sponsored clinical trial is underway outside the state’s major cities, bringing cutting edge research directly to rural and remote communities.

The trial, known as the YAAD clinical trial, is a Phase 2, double-blind, placebo-controlled study evaluating a new medicine designed to treat chemotherapy-induced nausea and vomiting. Researchers from the WA Country Health Service Clinical Trial Centre are leading the work in collaboration with clinicians in the Goldfields and Great Southern regions. Participants are randomly assigned into two groups: one receives the experimental medicine, while the other receives a placebo. Both groups continue to receive their planned chemotherapy treatment and standard-of-care antiemetic medication.

To support the study, dedicated in-house laboratory spaces have been established at the Albany and Esperance Health Campuses. These labs allow local teams to collect and process samples on site, while regional clinicians administer the medication and monitor participant health. The trial is being conducted in partnership with international oncology research company Eli Lilly and Company, marking a significant step for regional Australia’s role in medical innovation.

For patients in underserved areas, this trial represents more than a scientific milestone. It means access to potentially better supportive care without the need to travel hundreds of kilometres to a metropolitan hospital. If the new medicine proves effective, it could offer a much-needed option for the many cancer patients who struggle with nausea and vomiting despite existing treatments.

The results of the YAAD trial are expected in the coming years. Researchers hope the study will pave the way for more commercial trials in regional centres, expanding access to novel therapies and reinforcing the message that world-class medical research can happen anywhere.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.

← Back to all stories
Medical Disclaimer: Content on Curative News is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.